The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

While Ozempic and other drugs like it have proven effective in helping people lose weight, many gain it back when the injections stop. A new drug targets weight loss differently, leading to a more ...

Drugs that treat diabetes and weight loss have become a commercial and cultural phenomenon. But supply shortages and eye-watering prices have kept slimming jabs largely confined to the rich world, ...

The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

The appetite for weight-loss drugs, known as glp-1 agonists, has been insatiable since they hit the market a decade ago. In 2024 global spending on them reached $54bn, a figure that is sure to rise in ...